Skip to main content
. Author manuscript; available in PMC: 2016 Jun 1.
Published in final edited form as: Ann Rheum Dis. 2014 Aug 20;74(12):2236–2243. doi: 10.1136/annrheumdis-2014-205799

Figure 4.

Figure 4

Rituximab reduces myofibroblast volume in IgG4-related disease (IgG4-RD) lesions. H&E stain of consecutive skin biopsies from a patient with cutaneous IgG4-RD involvement from the same site, before (A and B) and after (C and D) treatment with rituximab. The dermal fibroblasts (arrows) exhibit abundant cytoplasm and large nuclei in active disease, and shrink after rituximab-mediated remission (original magnification: A and C 20×, B and D 40×).